Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer

Mastro, Lucia Del; Boni, Luca; Michelotti, Andrea; Gamucci, Teresa; Olmeo, N.; Gori, Stefania; Giordano, Monica; Garrone, Ornella; Pronzato, P.; Bighin, Claudia; Levaggi, Alessia; Giraudi, S.; Cresti, Nicola; Magnolfi, Emanuela; Scotto, Tiziana; Vecchio, C; Venturini, M.

doi:10.1001/jama.2011.991

Cited by 267 publications

(269 citation statements)

References 32 publications

Supporting

Mentioning

256

Contrasting

Unclassified

Order By: Relevance

“…122 Some studies, including randomized trials, have evaluated the role of menstrual suppression with gonadotropin-releasing hormone (GnRH; also known as LH-releasing hormone [LHRH]) agonists to preserve ovarian function during chemotherapy. [123][124][125][126][127][128][129][130][131] Some meta-analyses have shown that GnRH agonist may be beneficial for fertility preservation. [132][133][134] However, the impact of these meta-analyses are limited by flaws such as only examining women with breast cancer and only including trials that were not adequately powered and did not use blinding and/ or a placebo condition.…”

Section: Options For Femalesmentioning

confidence: 99%

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Coccia¹,

Pappo²,

Beaupin³

et al. 2018

J Natl Compr Canc Netw

253

194

View full text Add to dashboard Cite

Section: Options For Femalesmentioning

confidence: 99%

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Coccia¹,

Pappo²,

Beaupin³

et al. 2018

J Natl Compr Canc Netw

253

194

View full text Add to dashboard Cite

“…Despite limitations in study design and statistical power, the most recent randomized controlled trials suggest a protective ovarian effect in both HR+ and HR-patients and no signal for harm from a breast cancer recurrence standpoint 76,77 . A recent metaanalysis supports these findings 78 .…”

Section: Gnrh Agonists and Ovarian Function Preservationmentioning

confidence: 99%

Second international consensus guidelines for breast cancer in young women (BCY2)

et al. 2016

View full text Add to dashboard Cite

“…Gonadal protection through hormonal manipulation with GnRH analogs for FP in women treated with gonadotoxic chemotherapy has demonstrated conflicting results (3,(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26). Published clinical guidelines from clinical associations are variable in their recommendations regarding GnRH analogs.…”

Section: Usefulness Of Gonadotropin-releasing Hormone (Gnrh)mentioning

confidence: 99%

Fertility preservation in post-pubescent female cancer patients: A practical guideline for clinicians

et al. 2017

View full text Add to dashboard Cite

Abstract. Increasing accessibility of fertility preservation (FP) options has permitted women to retain fertility following anticancer therapies. Several published guidelines have made recommendations for FP however their implementation into practice is currently unknown. In this review, we aim to provide oncology clinicians practical information about FP options for post-pubescent female cancer patients and recommendations for care delivery in order to answer preliminary questions and help triage whether FP referral is appropriate. Herein, we present a resource for oncology providers to guide them with FP discussions. Key points that are discussed in this critical review include: i) All cancer patients beginning a new plan of care should be informed of potential fertility risk. ii) If a woman requests further information on FP interventions, referral to a FP clinic should be made. iii) Given the evolving technologies in this area, patients should be informed of those which are proven and unproven, with oocyte and embryo preservation recognized as standard practice. iv) Random start (independent of menstrual cycle day) techniques are available to minimize oncologic treatment delays. v) Specific protocols for ovarian stimulation may be center-specific. vi) There is unlikely an increased cancer recurrence risk as a result of stimulation protocols in women with hormone-sensitive cancers. vii) Lastly, given the absence of consensus in the literature, routine use of GnRH analogs is not recommended for all cancer patients, however may be considered in select cases, such as high-risk women in whom definitive FP is not possible or feasible.

show abstract

Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer

Abstract: clinicaltrials.gov Identifier: NCT00311636.

Cited by 267 publications

References 32 publications

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Second international consensus guidelines for breast cancer in young women (BCY2)

Fertility preservation in post-pubescent female cancer patients: A practical guideline for clinicians

Contact Info

Product

Resources

About